and many others. The letter highlights the fact that the industry relies on the FDA’s regulatory framework, and that “judicial activism” undermines it.
“Adding regulatory uncertainty to the already inherently risky work of discovering and developing new medicines will likely have the effect of reducing incentives for investment, endangering the innovation that characterizes our industry,” they wrote.Pear Therapeutics, which has three FDA-cleared prescription apps to help treat substance use disorder and insomnia, filed for bankruptcy last week, as the company struggled to get insurers to pay for its technology.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: Variety - 🏆 108. / 63 Consulte Mais informação »